Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform
M Pinto, V Silva, S Barreiro, R Silva, F Remião… - Ageing Research …, 2022 - Elsevier
The discovery of effective drugs for the treatment of neurodegenerative disorders (NDs) is a
deadlock. Due to their complex etiology and high heterogeneity, progresses in the …
deadlock. Due to their complex etiology and high heterogeneity, progresses in the …
PLGA-based nanoparticles for neuroprotective drug delivery in neurodegenerative diseases
A Cunha, A Gaubert, L Latxague, B Dehay - Pharmaceutics, 2021 - mdpi.com
Treatment of neurodegenerative diseases has become one of the most challenging topics of
the last decades due to their prevalence and increasing societal cost. The crucial point of the …
the last decades due to their prevalence and increasing societal cost. The crucial point of the …
Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer's disease
Alzheimer's disease (AD) is a chronic neurodegenerative disorder that accounts for about
60% of all diagnosed cases of dementia worldwide. Although there are currently several …
60% of all diagnosed cases of dementia worldwide. Although there are currently several …
Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier
G Tosi, B Bortot, B Ruozi, D Dolcetta… - Current medicinal …, 2013 - ingentaconnect.com
Nanomedicine is certainly one of the scientific and technological challenges of the coming
years. In particular, biodegradable nanoparticles formulated from poly (D, L-lactide-co …
years. In particular, biodegradable nanoparticles formulated from poly (D, L-lactide-co …
Multifunctional polymeric nanoplatforms for brain diseases diagnosis, therapy and theranostics
S Shakeri, M Ashrafizadeh, A Zarrabi, R Roghanian… - Biomedicines, 2020 - mdpi.com
The blood–brain barrier (BBB) acts as a barrier to prevent the central nervous system (CNS)
from damage by substances that originate from the blood circulation. The BBB limits drug …
from damage by substances that originate from the blood circulation. The BBB limits drug …
Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles—Focus on Alzheimer's and Parkinson's disease
S Hernando, E Santos‐Vizcaíno… - Wiley …, 2023 - Wiley Online Library
Neurodegenerative diseases (NDs) such as Alzheimer's disease (AD) and Parkinson's
disease (PD) are an accelerating global health problem as life expectancy rises worldwide …
disease (PD) are an accelerating global health problem as life expectancy rises worldwide …
PLA/PLGA nanoparticles for delivery of drugs across the blood-brain barrier
J Li, C Sabliov - Nanotechnology Reviews, 2013 - degruyter.com
The blood-brain barrier (BBB), which protects the central nervous system (CNS) from
unnecessary substances, is a challenging obstacle in the treatment of CNS disease. Many …
unnecessary substances, is a challenging obstacle in the treatment of CNS disease. Many …
Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases
A Cano, E Sanchez-Lopez, M Ettcheto… - …, 2020 - Taylor & Francis
Effective intervention is essential to combat the coming epidemic of neurodegenerative (ND)
diseases. Nanomedicine can overcome restrictions of CNS delivery imposed by the blood …
diseases. Nanomedicine can overcome restrictions of CNS delivery imposed by the blood …
Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood–brain barrier
G Tosi, RA Fano, L Bondioli, L Badiali, R Benassi… - …, 2011 - Taylor & Francis
Aim: Nanoneuroscience, based on the use polymeric nanoparticles (NPs), represents an
emerging field of research for achieving an effective therapy for neurodegenerative …
emerging field of research for achieving an effective therapy for neurodegenerative …
[HTML][HTML] Systemic delivery to central nervous system by engineered PLGA nanoparticles
Q Cai, L Wang, G Deng, J Liu, Q Chen… - American journal of …, 2016 - ncbi.nlm.nih.gov
Neurological disorders are an important global public health problem, but pharmaceutical
treatments are limited due to drug access to the central nervous system being restricted by …
treatments are limited due to drug access to the central nervous system being restricted by …
相关搜索
- polymeric plga neurodegenerative diseases
- drug delivery polymeric nanoparticles
- drug delivery neurodegenerative diseases
- alzheimer's disease plga nanoparticles
- systemic delivery plga nanoparticles
- blood brain polymeric nanoparticles
- blood brain delivery of drugs
- surface functionalization plga nanoparticles
- parkinson's disease synthetic nanoparticles
- brain bioavailability pegylated pla
- drug delivery brain barrier